Alzheimer's Tau Platform: Testing Tau-Directed Therapies
This study, called the Alzheimer's Tau Platform (ATP), is testing new treatments for early Alzheimer's disease. Researchers want to see if drugs like AADvac1 and Tau2, which target a protein called tau, can reduce tau buildup in the brain. They are also looking at these drugs in combination with donanemab, an antibody that targets another protein called amyloid. You might be able to join if you are between 50 and 80 years old and have early signs of Alzheimer's disease. The main goal is to see if these treatments can reduce tau in the brain, measured over 30 months using special brain scans (PET scans). This study is designed to test several treatments at once or one after another.
- Study design
- This is an interventional study with a planned enrollment of 900 participants. It's a platform trial, meaning multiple investigational products will be tested simultaneously or sequentially.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Tau deposition in the brain will be measured at 0, 6, 18, and 30 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Alzheimer's Tau Platform: Master Protocol
At a glance
Conditions
NCT06957418
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Butler Hospital Memory and Aging Program
Providence, Rhode Islandno site contact published
Recruiting
University of California, San Francisco
San Francisco, Californiano site contact published
Recruiting
Vanderbilt University Medical Center
Nashville, Tennesseeno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Adam Boxer, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco (UCSF), Memory and Aging Center
- Keith Johnson, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital (MGH), Harvard Medical School
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Reduction of brain tau deposition as measured by tau positron emission tomography (PET)0, 6, 18 and 30 months
To determine whether at least one tau therapy, either alone or in combination with donanemab, will produce a greater reduction in brain tau deposition as measured by 18F-MK-6240 PET compared to donanemab alone.